Apply to trial NCT07122076

A few quick questions so the study team can decide if you might be a fit.

RecruitingEarly Phase 1Biological intervention

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening